Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond

(2015) Gennaro Gadaleta-Caldarola et al.   Future Oncology

The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression

(2015) Siyuan Dong et al.   Journal of Hematology & Oncology

Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma

(2015) Guohua Lou et al.   Journal of Hematology & Oncology

Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: A systematic review and meta-analysis

(2015) Xingshun Qi et al.   Oncotarget

Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells

(2014) Dali Zhao et al.   CELLULAR SIGNALLING

Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model

(2014) Ke-Zhi Zhang et al.   Journal of Hematology & Oncology

Decreased TIP30 promotes Snail-mediated epithelial–mesenchymal transition and tumor-initiating properties in hepatocellular carcinoma

(2014) M Zhu et al.   ONCOGENE

Metformin Inhibits the Growth of Human Pancreatic Cancer Xenografts

(2013) Krisztina Kisfalvi et al.   PANCREAS

Sorafenib Down-regulates Expression of HTATIP2 to Promote Invasiveness and Metastasis of Orthotopic Hepatocellular Carcinoma Tumors in Mice

(2012) Wei Zhang et al.   GASTROENTEROLOGY

Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies

(2012) Justin N. Bottsford-Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

TIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in mice

(2012) A Li et al.   ONCOGENE

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

(2011) Bolin Liu et al.   CELL CYCLE

Tip30 Deletion in MMTV-Neu Mice Leads to Enhanced EGFR Signaling and Development of Estrogen Receptor-Positive and Progesterone Receptor-Negative Mammary Tumors

(2010) C. Zhang et al.   CANCER RESEARCH

Roles of hypoxia-inducible factor-1α (HIF-1α) versus HIF-2α in the survival of hepatocellular tumor spheroids

(2010) Heidi Menrad et al.   HEPATOLOGY

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease

(2010) Valter Donadon et al.   LIVER INTERNATIONAL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Metformin Disrupts Crosstalk between G Protein-Coupled Receptor and Insulin Receptor Signaling Systems and Inhibits Pancreatic Cancer Growth

(2009) K. Kisfalvi et al.   CANCER RESEARCH

New Users of Metformin Are at Low Risk of Incident Cancer: A cohort study among people with type 2 diabetes

(2009) G. Libby et al.   DIABETES CARE

Biology of hypoxia-inducible factor-2α in development and disease

(2008) S A Patel et al.   CELL DEATH AND DIFFERENTIATION

Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis

(2008) Jing Yang et al.   DEVELOPMENTAL CELL

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY